docetaxel anhydrous has been researched along with Disbacteriosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, Y; Lai, H; Long, Z; Lu, J; Lv, D; Mao, X; Wang, S; Wu, K; Zhong, C; Zhong, W; Zhou, X | 1 |
1 other study(ies) available for docetaxel anhydrous and Disbacteriosis
| Article | Year |
|---|---|
Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis.
Topics: Animals; Anti-Bacterial Agents; Docetaxel; Dysbiosis; Feces; Humans; Interleukin-6; Lipopolysaccharides; Male; Mice; NF-kappa B; Prostatic Neoplasms; Proteobacteria; RNA, Ribosomal, 16S; STAT3 Transcription Factor | 2022 |